Richard Pazdur

2 ta ish

United States Food and Drug Administration

1. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

   Patricia Cortazar, Lijun Zhang, Michael Untch +34

   Sharh maqola20144 iqtibos

   ABIABI:AkademIndex/2026.other.434433

2. Trends in the approval of cancer therapies by the FDA in the twenty-first century

   Emma Scott, Andrea Baines, Yutao Gong +10

   Sharh maqola20232 iqtibos

   ABIABI:AkademIndex/2026.other.079164